David Saxon

how are we how should we think about the magnitude of that impact on gross margins kind of the cadence of that of how that hits the P and L?

operating margin down year-on-year in the first quarter, but guiding to expansion for the full year

Joe, based on your answer to a previous question, it sounds like U.S. volume growth should probably be slower than international

how much of that was the market and this consumer softness you've talked to versus rationalizing the legacy hydrogel

I think you said flat to up low single digits for fiscal 'twenty six. It looks like the competitive IUD is going to launch in the '26. Is there anything embedded in that ParaGuard expat expectation

any residual impact from like the distributor channel inventory dynamic you talked about a couple of quarters ago or the private label conversion from Clarity to MyDay.

I think you talked about doing $2 billion over the next three years. I think you've been historically in the mid to upper teens. From a free cash flow margin. What's that $2 billion imply

has that normalized? Or will there be any impact in the fiscal fourth quarter? And then as we think about fiscal '26, does any of that distributor inventory, the Clarity, the APAC e-commerce stuff,...